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Background: Syzygium campanulatum Korth (Myrtaceae) is an evergreen shrub rich in phenolics, flavonoid
antioxidants, and betulinic acid. This study sought to investigate antiangiogenic and anti-colon cancer effects of S.C.
standardized methanolic extract.
Methods: Betulinic acid was isolated from methanolic extract by crystallization and chromatography techniques. S.
C. methanolic extract was analyzed by UV-Vis spectrophotometry, FTIR, LC-MS, and HPLC. Antiangiogenic effect was
studied on rat aortic rings, matrigel tube formation, cell proliferation and migration, and expression of vascular
endothelial growth factor (VEGF). Antitumor effect was studied using a subcutaneous tumor model of HCT 116
colorectal carcinoma cells established in nude mice.
Results: Analysis by HPLC, LC-MS and FTIR confirm presence of betulinic acid in S.C. methanolic extract.
Quantitative analysis by HPLC indicates presence of betulinic acid in S.C. extract at 5.42 ± 0.09% (w/w).
Antiangiogenesis study showed potent inhibition of microvessels outgrowth in rat aortic rings, and studies on
normal and cancer cells did not show any significant cytotoxic effect. Antiangiogenic effect was further confirmed
by inhibition of tube formation on matrigel matrix that involves human endothelial cells (IC50 = 17.6 ± 2.9 μg/ml). S.
C. extract also inhibited migration of endothelial cells and suppressed expression of VEGF. In vivo antiangiogenic
study showed inhibition of new blood vessels in chicken embryo chorioallantoic membrane (CAM), and in vivo
antitumor study showed significant inhibition of tumor growth due to reduction of intratumor blood vessels and
induction of cell death.
Conclusion: Collectively, our results indicate S. campanulatum as antiangiogenic and antitumor candidate, and a
new source of betulinic acid.Background
Syzygium campanulatum Korth (S.C.) is an evergreen
shrub from the family Myrtaceae. It is known as “kelat
paya” in Malaysia and Singapore where it is frequently
grown as a hedge. The shrub is adapted to rapid growth
under harsh conditions and can grow into tree when left
alone (Figure 1) [1]. The fruits look like black berries,
and can be seen from April-May and December-January.* Correspondence: abedaisheh@yahoo.com; aminmalikshah@gmail.com
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reproduction in any medium, provided the orS.C. exists in 2 varieties that can be distinguished by the
color of the young leaves and flowers; the first variety has
yellow leaves and white-creamy flowers, and the second
variety has red leaves and red flowers.
Angiogenesis is a critical process in various physiological
conditions such as wound healing, female reproductive
system, and embryonic development. It also plays an
important role in various pathological conditions including
growth and metastasis of solid tumors, rheumatoid arth-
ritis, proliferative diabetic retinopathy, and psoriasis [2,3].
Inhibition of angiogenesis, which was suggested by Judah
Folkman in 1971 [4], is now considered one of the most
promising strategies to combat cancer. Recently, there has
been a great interest in angiogenesis modulators for therapytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Different parts of Syzygium campanulatum Korth. Fruit buds (A), flowers (B), ripe fruits (C), and whole tree (D).
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several plant-derived compounds have shown promising
antiangiogenic and antitumor effects such as ursolic acid
[5], oleanolic acid [6], lupeol [7], betulinic acid [8], green
tea catechins [9], resveratrol from grapes [10], quercetin
[11], rosmarinic acid [12], genistein [13] and curcumin [14].
Despite the widespread availability of S.C. in Malaysia,
Singapore and neighboring countries, there is scarcity of
data about its medicinal use and pharmacological effect.
In a previous screening study, S.C. extracts exhibited
potent inhibition of microvessels outgrowth in rat aortic
rings which indicates possible antiangiogenic effect [15].
Therefore, this study was undertaken in order to
standardize the S.C. methanolic extract including isolation
of 3β-3-Hydroxy-lup-20(29)-en-28-oic acid (betulinic acid,BA) (Figure 2), determination of total phenolics, total
flavonoids, BA content, and UV-Vis and FTIR fingerprints
of the leaf extract. The study also sought to investigate the
mechanism of angiogenesis inhibition, and anti-colon
cancer effect of S.C. standardized extract. To our know-
ledge, this is the first study that addresses standardization
and the pharmacological activity of S. campanulatum.
Methods
Cell lines and reagents
HCT 116 human colorectal carcinoma, MCF-7 human
breast cancer, CCD-18Co human normal fibroblasts, and
MCF-10A human normal epithelial cell lines were pur-
chased from American Type Culture Collection (ATCC;
Manassas, Virginia). Human umbilical vein endothelial
Figure 2 Chemical structure of betulinic acid.
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supplied with endothelial cell growth supplements (ECGS)
were obtained from ScienCell (Carlsbad, California). RPMI
1640, DMEM, MEM and M199 cell culture media, fetal
bovine serum (FBS), MEM vitamins, and non-essential
amino acids were obtained from Bio-Diagnostics
(Petaling Jaya, Selangor, Malaysia). Human VEGF assay
kit was obtained from IBL (Aramachi, Takasaki-Shi, Gunma,
Japan). Betulinic acid, ursolic acid (UA), oleanolic acid (OA),
penicillin/streptomycin (PS) solution, XTT reagent with
phenazine methosulfate (PMS), suramin, amphotericin B,
aprotinin, 6-aminocaproic acid, L-glutamine, thrombin,
human insulin, epidermal growth factor, and gentamicin
were obtained from Sigma–Aldrich (Kuala Lumpur,
Malaysia). Fibrinogen was obtained from Calbiochem (Shah
Alam, Selangor, Malaysia). Matrigel matrix (10 mg/ml) was
obtained from SABiosciences (Frederick, Maryland).
Analytical and HPLC grade solvents were obtained from
Avantor Performance Materials (Petaling Jaya, Selangor,
Malaysia).Plant material and extraction
S.C. leaves were collected from the main campus of
Universiti Sains Malaysia (USM) during November 2008.
The plant was authenticated by the Herbarium of School
of Biological Sciences, USM, where a voucher specimen
was deposited (Ref. No. 11047). Leaves were washed,
oven-dried at 40°C for 4 days, and grinded into fine
powder. The powder (550 g) was macerated in 2L methanol
for 48 h in water bath at 50°C with intermittent shaking.
The extract was filtered and methanol was evaporated at
50°C using rotavapor, and further dried at 50°C for 48 h.Cell culture
HUVECs were cultured in ECM containing 5% FBS, 1%
PS and 1% ECGS; HCT 116 cells were cultured in
RPMI 1640 containing 10% FBS and 1% PS; MCF-7 andCCD-18Co cells were cultured in DMEM supplemented
with 10% FBS and 1% PS. MCF-10A cells were cultured in
MEM enriched with 10% FBS, 1% PS, 1% sodium
pyruvate, 1% nonessential amino acids, 1% L-glutamine,
1% MEM vitamins, human insulin (5 μg/ml), and
epidermal growth factor (EGF) (100 ng/ml). Cells were
propagated as monolayer at 37°C and 5% CO2.
Phytochemical analysis
Estimation of total phenolics, total flavonoids and
antioxidant effect
Total phenolics content was estimated using a colorimetric
assay [16]. Extract (100 μl at 1.0 mg/ml in methanol) was
added to 750 μl Folin-Ciocalteau reagent and incubated for
5.0 min in the dark at RT. Subsequently, 750 μl sodium bi-
carbonate (60 g/L) was added, incubated in the dark at 30°C
for 90 min, and absorbance was measured at 725 nm. Gallic
acid was used as a standard (50–1600 μg/ml), and the
results are expressed as %w/w gallic acid equivalents.
Total flavonoids content was determined using quercetin
as a standard [17]. The standard and extracts (500 μl) were
added to 0.1 ml 10% (w/v) of aluminium chloride, 0.1 ml of
1.0 M potassium acetate, 1.5 ml methanol and 2.8 ml water.
Potassium acetate and aluminium chloride were replaced
with water in the blank reaction. The reaction mixture was
incubated for 30 min at RT, and absorbance was
taken at 415 nm. The results are presented as %w/w
of total flavonoids.
DPPH scavenging activity was determined as described
previously [18]. DPPH at a final concentration of 50 μM
was added to S.C. extract at 12.5–200 μg/ml, incubated
in the dark at 30°C for 30 min. Subsequently, absorbance
was measured at 517 nm, and DPPH scavenging effect
was calculated as the following;
DPPH scaveniging effect
¼ 1 absorbance of samples  blankð Þð =
absorbance of negative control blankð ÞÞ  100:
The results are presented as mean percentage inhib-
ition ± SD (n = 3).
Isolation and characterization of betulinic acid
BA was isolated from S.C. methanolic extract as described
previously with some modifications [19]. In brief, 50 g of
the methanolic extract was dissolved in 150 ml methanol
and was kept at 2–8°C for overnight. Subsequently, the
resulted solid was collected by filtration, and the filtrate
was concentrated again and kept at 2–8°C for overnight.
The solid from both cycles was pooled, and washed
3× with ice-cold methanol to give 2.5 g of BA-rich
fraction. BA was further purified from this fraction by
column chromatography as the following; 1 g of the
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form and mixed with 5 g silica gel 60 (0.063–0.200 mm),
the solvent was evaporated in a fume hood and the mix-
ture was further dried for 30 min at 50°C. The column
(20” × 1”) was packed with 50 g silica gel 60 (0.063–0.200
mm) prepared in the mobile phase. Elution was performed
with n-hexane: ethyl acetate at 8:2 (v/v). Fractions (10 ml)
were collected and tested by HPLC versus BA standard as
described previously [19]. The fraction of highest purity
(100 mg) was further characterized by FTIR and liquid
chromatography-mass spectrometry (LC-MS).
LC-MS analysis of the BA reference compound,
isolated BA, BA-rich fraction and the S.C. methanolic
extract was performed using a Micro TOF-Q ESI Mass
Spectrometer (Bruker) coupled with a Dionex U3000
HPLC system. Liquid chromatography was carried out
on a reverse phase HPLC using Acclaim RSLC C18
column (2.2 μm, 2.1 × 50 mm). The mobile phase
consisted of 0.1% formic acid in water (A) and acetonitrile
(B), and a gradient elution was used (5–95%) of B in 15
min at a flow rate of 0.3 ml/min. Injection volume was 10
μl, and mass analysis was carried out in the negative ion
mode within the range 100–1000 m/z.Quantification of betulinic acid in S.C. methanolic extract
Analytical chromatography was carried out using Agilent
1100 HPLC system, on ZORBAX Eclipse Plus C18
column (5 μm, 4.6 × 250 mm). The mobile phase consisted
of A (Acetonitrile), B (0.1% H3PO4 in water). The elution
program was isocratic at 86% (A) and 14% (B) for 20 min,
at a flow rate of 1 ml/min. Injection volume was 10 μl, and
the wavelength was 210 nm. BA, ursolic acid (UA) and
oleanolic acid (OA) reference compounds were also
analyzed. Linear regression equation of BA calibration
curve (y = 0.3708x + 9.2599, R2 = 1.0) was then applied to
calculate BA concentration in the S.C. extract, and
the results are presented as %w/w.Rat aortic rings angiogenesis model
Antiangiogenesis effect was firstly investigated using
the 3-dimensional rat aortic rings model as described
previously [15,20,21]. Basically, aortic rings were
seeded in 48-well plate containing 500 μl M199
medium containing fibrinogen (3.0 mg/ml), aprotinin
(5.0 μg/ml) and L-glutamine (1.0% w/v), followed by
addition of 10 μl thrombin (50 U/L). After 90 min
incubation, 500 μl M199 medium was added; this medium
was supplemented with FBS (20% v/v), L-glutamine
(2.0 mM), 6-aminocaproic acid (1.0 mg/ml), amphotericin B
(2.5 μg/ml), gentamicin (60 μg/ml), and the treatment com-
pounds. After 4-days incubation at 37°C and 5% CO2, the
upper layer medium was replaced with a fresh one. On day
5, the distance of outgrowth of the sprouting microvesselswas measured [15,22], and the mean percentage growth
inhibition was calculated (n = 3).
Cell viability
Cell viability was determined by the XTT test as
described previously [23]. Briefly, cells were treated for
48 h, the old culture medium was replaced with a fresh
one containing XTT (100 μg/ml) and PMS (1.0 μg/ml),
and incubated for 4 h. Absorbance was then measured
at 450 nm using a microplate reader (Thermo Fisher
Scientific, Ratastie, Vantaa, Finland). The results are
presented as percentage inhibition to the negative control
(0.5% DMSO) as the following:
Percentage inhibition ¼ 1 ODSamples ODBlank
 
=
ODVehicle ODBlankð ÞÞ  100
The median inhibitory concentrations (IC50s) were
calculated using the dose response curves (n = 3).
HUVECs tube formation on matrigel matrix
Matrigel tube formation of HUVECs was investigated as
previously described with minor modifications [24,25].
In brief, 2 × 105 treated HUVECs (150 μl) were added to
48-well plate containing 150 μl solidified matrigel and
incubated for 6 h. Subsequently, the tube-like structures
were visualized and photographed under light microscopy
at 4× magnification. The images were analyzed by measur-
ing the area occupied by the tube-like structures using
ScnImage software package (available free online). The
results are presented as percentage inhibition to untreated
cells, and the IC50 was calculated using the dose response
curve (n = 4).
Determination of VEGF concentration in HUVECs lysates
Concentration of human VEGF-165 in HUVEC cell
lysates was determined by human VEGF ELISA kit
according to manufacturer’s instructions. HUVECs were
treated for 6 h, washed with PBS, and cell lysates
were prepared. Calibration curve of VEGF standard
was prepared simultaneously, and concentration of
VEGF in cell lysates was then determined by applying
the VEGF linear regression equation, y = 0.0021x + 0.0585,
R2 = 0.999 (n = 3).
Cell migration
Effect of S.C. extract on HUVECs migration was studied
by the wound healing assay as described previously [26].
Briefly, cells were seeded in 6-well plates at 1 × 106 cells/
well in 3.0 ml medium, and were allowed to reach 100%
confluency. Subsequently, the cell monolayer was scratched
with a sterile 200 μl micropipette tip, washed with PBS, and
3.0 ml fresh medium containing treatments was added. The
wounds were photographed (8 microscopic fields per well
Figure 3 HPLC analysis of S.C. methanolic extract. BA, UA and
OA standard compounds (A), S. campanulatum methanolic extract
(B), BA-rich fraction (C), and isolated BA (D).
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immediately and after a specified period of treatment.
The distance of cell-free wounds was measured by
Leica Quin software in a minimum of 20 points/field,
and the percentage of wound closure was calculated
relative to zero time treatment using the formula;
% Wound closure ¼ ð1 ðdistance at xh=
distance at zero timeÞÞ  100
Where x refers to the treatment time in hours.
Chicken embryo chorioallantoic membrane assay
The chicken embryo chorioallantoic membrane (CAM)
assay was performed as described previously [27,28].Fertile eggs were incubated for 5 days at 37°C in a humidi-
fied incubator with intermittent manual rotation. On day
5, the large blunt edge was covered with a small piece of
adhesive tape, where a small hole was made and 2–5 ml
albumin was withdrawn and the eggs were incubated
horizontally for 2 h. Subsequently, the eggs were covered
with adhesive tape and a circular window was made.
Treatments were prepared in ethanol at 20 mg/ml and
applied on Whattman filter paper discs at 200 and
100 μg/disc; discs for negative control received the
same volume of ethanol. Ethanol was evaporated and
the discs were applied directly onto the CAM through the
window (n = 12). After 24 h, CAMs were illuminated and
photographed under dissecting microscope.
In vivo antitumor effect
Sixteen mice aged 6–8 weeks with average weight of 25 g
were injected subcutaneously, in right flank, with 5 × 106
HCT 116 cells in 150 μl RPMI medium. After 7–10 days,
animals with uniform tumor size were divided into 2
groups of 5–6 animals. Treatment was performed by
mixing S.C. extract with animal food at 0.25% (w/w), and
tumor dimensions were measured at 7-days intervals by a
caliber in 2 angles, length and width [29]. Tumor size was
then calculated as described previously [29-31] using the
following equation;
Tumor size mm3
  ¼ W þ Lð Þ=2ð Þ∧3  2
Where W is the width and L is the length.
After 28-days treatment, animals were euthanized and
the tumors were collected, cross sectioned, and stained
with eosin/hematoxylin for microscopic examination.
Experimental animals
Athymic NCR nu/nu nude mice were obtained from
Taconic Farms Inc., USA. Mice were housed in spe-
cific pathogen free (SPF) cages, and supplied with
autoclaved food, water and bedding. The procedures
were approved by USM Animal Ethics Committee
(Ref. PPSG/07(A)/044/(2010)(59)).
Sprague Dawley male rats were obtained from animal
breeding facility at USM. Animals were euthanized by
CO2 and the thoracic aortas were collected. Experiments
were performed according to the guidelines of USM
Animal Ethics Committee and had their approval
(Ref. USM/PPSF/50 (084) Jld.2).
Statistical analysis
The results are presented as mean ± SD. Differences
between groups were analyzed by the student t-test
or One-way ANOVA and were considered significant
at P < 0.05.
Figure 4 In vitro inhibition of angiogenesis. Rat aortic rings (A): Untreated (1), suramin at 100 μg/ml (2), and S.C. methanolic extract at 100 μg/ml
(3). Inhibition of HUVECs cell migration (B and C): zero time treatment (B1 and C1), methanolic extract at 100 μg/ml (B2) and at 50 μg/ml (C2), Untreated
cells (B3 and C3). The lines are drawn for explanation.
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Phytochemical analysis
The methanolic extract of S.C. was obtained at rela-
tively high percentage yield (16.4%, w/w). Preliminary
phytochemical screening showed presence of high concen-
tration of total phenolics (38 ± 1.3%), total flavonoids
content (30 ± 3.7%), and also showed a potent DPPH
scavenging activity, IC50 33.0 ± 1.0 μg/ml.
FTIR and UV-Vis spectroscopy fingerprints
S.C. extract was analyzed by FTIR and UV-Vis spectroscopy
(Additional file 1: Figures S1 and S2). In FTIR the strong
and broad band at 3314 cm-1 corresponds to stretching
vibration of O–H group, the peak at 2930 cm-1 refers to
stretching vibration of aliphatic chains, peaks at 1615 cm-1,
1521 cm-1, and 1449 cm-1 correspond to C–C stretching inaromatic rings, the peak at 1697 cm-1 corresponds to
stretching vibration of the carbonyl group C=O, the bands
at 1351 cm-1 and 1232 cm-1 refer to –C–OH deformation
vibrations, and the band at 1044 cm-1 refers to –C–OH
stretching vibrations. The UV-Vis spectrum showed
absorption maxima at 273.1 nm.
Isolation and characterization of betulinic acid
BA-rich fraction (72% purity) was obtained at relatively
high percentage yield (5%) by repeated crystallization and
washing of the S.C. methanolic. BA of higher purity (95%)
was then isolated from the BA-rich fraction by column
chromatography at a percentage yield of 10%. Identity of
BA was firstly confirmed by comparing its HPLC retention
time (10.6 ± 0.02 min) with BA reference compound
(Rt: 10.54 ± 0.02 min). The BA-rich fraction also contained
Figure 5 Inhibition of tube formation on Matrigel matrix. Untreated cells (A), suramin (B), (C-G) S.C. methanolic extract at 100, 75, 50, 25 and
12.5 μg/ml, and analysis showing a dose dependent inhibition of tube formation (H).
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of ursolic acid (Rt: 12.7 ± 0.1 min) (Figure 3).
Identity of BA was then confirmed by FTIR analysis;
the dominant absorbance bands are located at 3450,
2939, 2872, 1689, 1642, 1455, 1377, 1232, 1190, 1142,
1036, and 884 cm-1. By comparing the band positions of
BA standard with isolated BA, identical spectra were
obtained which confirm the identity of isolated BA
(Additional file 1: Figure S3). BA identity was further
confirmed by MS analysis; BA reference and isolated
compound was eluted at the same retention time
(10.56 min), and the mass spectral isotopic pattern of
isolated BA matches that of reference BA (455.35,
456.35 and 457,35 m/z). LC-MS analysis of methanolic
extract also showed presence of compound with a mass of
455.35 m/z (Additional file 1: Figure S5). Taken togetherthese results confirm presence of BA in S.C. methanolic
leaf extract. HPLC quantitative analysis of BA in the
S.C. extract indicates presence of the compound at
5.42 ± 0.09% (w/w).
In vitro antiangiogenesis effect
Antiangiogenesis effect of S.C. extract was studied by
various tests that target different angiogenesis hallmarks.
Preliminary testing was performed on rat aortic rings
which involve all steps of the angiogenesis cascade
except blood flow. The results showed strong inhibition
of microvessels outgrowth at 100 μg/ml (65 ± 11)%,
compared to 0.0 ± 10.7% by the vehicle (0.5% DMSO)
and 100 ± 1.0% by suramin at 100 μg/ml (Figure 4A).
However, this inhibitory effect can be due to nonselective
cytotoxic or interference with the angiogenesis cascade. In





0.5% DMSO 100 μg/mLl 50 μg/ml Suramin 25 μg/ml
12 74 ± 10% 36 ± 6% 50 ± 7% 53 ± 5%
18 87 ± 6% 41 ± 4% 64 ± 7% 84 ± 6%
Results are presented as percentage of wound closure ± SD (n = 3).
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cytotoxicity of S.C. extract was evaluated on endothelial
versus other normal and cancer cells. The extract, at
the same concentration used in rat aortic rings test
(100 μg/ml), did not show any significant cytotoxicity on all
tested cell lines; the percentage of growth inhibition was
0.0 ± 4.0% (HUVECs), 2.0 ± 1.0% (MCF-10A), 2.0 ± 3.0%
(CCD-18Co), 12 ± 0.0% (MCF-7), and 15 ± 2.0% (HCT
116). These results indicate the extract is noncytotoxic;
hence we can be conclude that inhibition of microvessels
outgrowth observed in rat aortic rings is not due to non-
selective cytotoxicity, but due to interference with
angiogenesis process.
Antiangiogenic effect was further studied using HUVECs
tube formation on matrigel matrix which measuresFigure 6 In vivo inhibition of angiogenesis using Chicken embryo CA
with S.C. methanolic extract at 200 μg/disc (C) and 100 μg/disc (D).differentiation of endothelial cells. Matrigel is a tumor-
derived matrix that contains all components present in
basement membranes and the growth factors required to
promote differentiation of endothelial cells to start forming
blood vessels-like structures [32,33]. Our results
showed potent inhibition of tube formation in dose
dependent manner with IC50 of 17.6 ± 2.9 μg/ml
(Figure 5). Inhibition of tube formation may be medi-
ated by interference with plasminogen activators
(PAs), matrix metalloproteinases MMPs, growth fac-
tors, and cell adhesion molecules [34,35].
VEGF is a key growth factor overexpressed in most
solid tumors; it initiates angiogenesis process that is
required for tumor growth and metastasis by inducing
proliferation, migration, sprouting and tube formation of
endothelial cells [36-39]. Therefore, suppression of VEGF
expression is considered as a good target in treatment
of angiogenesis dependent diseases. In this study
effect on VEGF expression in endothelial cells was
investigated as a possible mechanism of S.C. extract
antiangiogenic effect; the results showed significant
suppression of VEGF expression in HUVECs lysates
at 100 μg/ml (12 ± 1.8 pg/ml) compared to untreated
cells (26 ± 2.7 pg/ml), P = 0.001.Ms. Untreated CAM (A), treated with suramin at 25 μg/disc (B), treated
Figure 7 Inhibition of the subcutaneous tumor growth in nude
mice. A time course of tumor size measurement (A), cross sections
of tumor tissues (B): untreated (1), and treated with S.C. methanolic
extract at 0.25% w/w (2). Pictures were taken at 5× magnification. (*)
refers to P < 0.05.
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inhibition of HUVECs migration by S.C. extract at
100 and 50 μg/ml (Figure 4B and C). It is noteworthy
that S.C. extract was more potent than suramin, a
standard angiogenesis inhibitor (Table 1), P = 0.001.
In vivo antiangiogenesis effect
In vivo antiangiogenic effect was investigated on
chicken embryo CAMs. Results show inhibition of CAMs
vascularization by S.C. extract at 200 and 100 μg/disc.
Figure 6A shows normal vascularization of untreated
CAMs with primary, secondary and tertiary vessels and
dendritic branching. On the other hand, CAMs treated
with S.C. extract showed distorted vasculature or absence
of blood vessels (Figure 6B-D).
Taken together, inhibition of microvessels outgrowth
in rat aortic rings, inhibition of HUVECs migration,
inhibition of tube formation on matrigel matrix and
interference with vascularization of chicken embryo
CAMs provide evidence about antiangiogenic effect of
S.C. extract, which can be explained due to suppression of
VEGF expression in endothelial cells.
Phytochemical analysis of S.C. extract showed
presence of high phenolics, flavonoids and BA content,
which may explain the antiangiogenic effect of S.C.
extract. Antiangiogenic effect of phenolic compounds
such as flavonoids has been reported by several research
groups worldwide, with different mechanisms of action
such as suppression of VEGF and HIF-1α expression
[40]. Recent studies that explored the mechanism of
BA antiangiogenic effect in different types of cancer
concluded that the compound inhibits tumor angiogenesis
by suppressing expression of the signal transducer
and activator of transcription 3 (STAT3), hypoxia inducible
factor-1α and VEGF [41,42].
In vivo antitumor effect
HCT 116 cells provides an invasive model of human
colorectal carcinoma [43], which depends highly on
angiogenesis for the tumor to grow and metastasize [44].
In vivo antitumor study showed significant inhibition of
tumor growth by treatment with S.C. methanolic extract
at 0.25 w/w% (Figure 7A). Microscopic examination of
tumor cross sections showed significant reduction in
the number of intratumor blood vessels in treated
(4.6 ± 0.5/microscopic field) compared to untreated
animals (7.8 ± 1.2/microscopic filed), P = 0.001. More-
over, histological examination of tumor cross sections
revealed more abundant apoptotic/necrotic regions in
tumors of treated animals compared to untreated ani-
mals (Figure 7B). It is noteworthy that S.C. extract
did not show obvious toxicity to treated mice, and no
significant difference was observed in weight gain
between treated (0.3 ± 7.0)% and untreated animals(5.0 ± 4.0)%, P = 0.001. Anti-colon cancer effect of S.C.
extract may be attributed to inhibition of tumor
angiogenesis which often leads to decreased nutrient
and oxygen supply, and consequently decreased tumor
growth, increased extent of tumor necrosis and ultimately
decreased tumor size.
Conclusion
Collectively, our data showed that S.C. methanolic
extract is rich in phenolics, flavonoids and betulinic
acid. The extract suppressed expression of VEGF in
endothelial cells, and inhibited angiogenesis and
tumor growth in nude mice. A possible mechanism
of the anti-colon cancer activity of S.C. extract is the
inhibition of tumor angiogenesis. Antiangiogenic and
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partly, due to the high flavonoids and betulinic acid
content. Thus, our findings suggest that S.C. extract
could be an interesting antiangiogenic candidate that
targets the VEGF signaling pathway. S. campanulatum
may have applications in colon cancer adjuvant therapy
and other angiogenesis related diseases.
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Additional file 1: Figure S1. FT-IR spectrum of S. campanulatum
methanolic extract. Figure S2 UV-VIS spectrum of S. campanulatum
methanolic extract. Figure S3 An overlay of FTIR spectra of isolated and
standard betulinic acid. Figure 4S LC-MS analysis of betulinic acid.
Standard compound from Sigma (A), isolated compound from S.
campanulatum methanolic extract (B), BA-rich fraction from S.
campanulatum methanolic extract (C), isotopic pattern of standard
betulinic acid (D) and isolated betulinic acid (F). Figure 5S LC-MS analysis
of betulinic acid in S. campanulatum methanolic extract. Betulinic acid is
compound number 18 with a retention time of 10.57 min, a mass
spectral isotopic pattern of (M-1) 455.3532, 456.3561, and 457.3594 m/z,
and molecular formula C30H48O3.
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